Last updated on April 2019

A Study to Test Safety Tolerability and the Way the Body Absorbs Distributes and Gets Rid of a Study Drug Called MOR106 in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis


Brief description of study

The clinical study consists of two parts:

  • Part 1 with healthy volunteers.
  • Part 2 including subjects with moderate to severe atopic dermatitis (a skin disease).

For Part 1 the main goal of the study is to compare the safety, tolerability, and exposure of administration of the test drug via an injection in a skin layer just under the surface (subcutaneous), to administration of the test drug into the vein (intravenous).

For Part 2 the main goal of the study is to assess the safety and tolerability of administration of the test drug via an injection in a skin layer just under the surface (subcutaneous) during 12 weeks of treatment.

Clinical Study Identifier: NCT03689829

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.